Selecta Biosciences Company Profile (NASDAQ:SELB)

About Selecta Biosciences (NASDAQ:SELB)

Selecta Biosciences logoSelecta Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its product candidates are in various stages of clinical and preclinical development. Its SVP technology encapsulates an immunomodulator in biodegradable nanoparticles to induce antigen-specific immune tolerance to mitigate the formation of anti-drug antibodies (ADAs) in response to life-sustaining biologic drugs. The Company's lead product candidate, SEL-212, is a combination of a therapeutic enzyme and its SVP technology designed to be the biologic treatment for gout.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:SELB
  • CUSIP: N/A
  • Web: www.selectabio.com
Average Prices:
  • 50 Day Moving Avg: $14.34
  • 200 Day Moving Avg: $14.96
  • 52 Week Range: $10.26 - $28.00
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.47
  • P/E Growth: 0.00
Profitability:
  • Net Margins: -715.40%
  • Return on Equity: -76.21%
  • Return on Assets: -51.58%
Debt:
  • Debt-to-Equity Ratio: 0.17%
  • Current Ratio: 5.37%
  • Quick Ratio: 5.37%
Misc:
  • Average Volume: 83,580 shs.
 

Frequently Asked Questions for Selecta Biosciences (NASDAQ:SELB)

What is Selecta Biosciences' stock symbol?

Selecta Biosciences trades on the NASDAQ under the ticker symbol "SELB."

How were Selecta Biosciences' earnings last quarter?

Selecta Biosciences, Inc. (NASDAQ:SELB) posted its quarterly earnings data on Thursday, May, 11th. The company reported ($0.82) earnings per share for the quarter, beating the consensus estimate of ($1.22) by $0.40. The company earned $0.14 million during the quarter. Selecta Biosciences had a negative return on equity of 76.21% and a negative net margin of 715.40%. View Selecta Biosciences' Earnings History.

Where is Selecta Biosciences' stock going? Where will Selecta Biosciences' stock price be in 2017?

3 brokerages have issued 1-year price objectives for Selecta Biosciences' stock. Their predictions range from $25.00 to $32.00. On average, they anticipate Selecta Biosciences' share price to reach $28.33 in the next twelve months. View Analyst Ratings for Selecta Biosciences.

What are analysts saying about Selecta Biosciences stock?

Here are some recent quotes from research analysts about Selecta Biosciences stock:

  • 1. According to Zacks Investment Research, "Selecta Biosciences, Inc. is a biopharmaceutical company which develops targeted immunotherapies and vaccines. Its product pipelineincludes gene therapy, food allergy, malaria; SEL-212, which is a therapeutic enzyme indicated for refractory gout; SEL-070, which is indicated for smoking cessation and relapse prevention; SEL-701, which is indicated for the treatment of human papillomavirus associated cancer and SEL-212 consists of SVP-Rapamycin co-administered with pegsiticase, its pegylated uricase. Selecta Biosciences, Inc. is based in Watertown, United States. " (4/20/2017)
  • 2. Needham & Company LLC analysts commented, "Selecta presented initial Phase II multi-dose data for SEL-212 on its 4Q16 earnings call. We believe this early data is very encouraging as a clinically active monthly dose appears to have been reached. Dosing continues with 2 additional cohorts. The next update is expected at a conference in June. We remain buyers of SELB as we believe they have both a promising clinical candidate in SEL-212 and a broadly applicable platform to induce tolerance to anti-drug antibodies." (3/28/2017)

Who are some of Selecta Biosciences' key competitors?

Who are Selecta Biosciences' key executives?

Selecta Biosciences' management team includes the folowing people:

  • Werner Cautreels Ph.D., Chairman of the Board, President, Chief Executive Officer
  • Omid Farokhzad M.D., Co-Founder, Director
  • David Siewers, Chief Financial Officer, Treasurer
  • Lloyd Johnston Ph.D., Chief Operating Officer, Senior Vice President - Research & development
  • Takashi Kei Kishimoto Ph.D., Chief Scientific Officer
  • David Abraham J.D., Chief Compliance Officer, General Counsel, Corporate Secretary
  • Peter Keller, Chief Business Officer
  • Earl Sands M.D., Chief Medical Officer
  • Timothy C. Barabe, Independent Director
  • Peter Barton Hutt, Independent Director

When did Selecta Biosciences IPO?

(SELB) raised $64 million in an initial public offering (IPO) on Wednesday, June 22nd 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank and Stifel served as the underwriters for the IPO and Canaccord Genuity and Needham & Company were co-managers.

Who owns Selecta Biosciences stock?

Selecta Biosciences' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Polaris Venture Management Co. V L.L.C. (0.00%), Flagship Pioneering Inc. (0.00%), FMR LLC (0.00%), JPMorgan Chase & Co. (0.00%), Sphera Funds Management LTD. (0.00%) and Perceptive Advisors LLC (0.00%). Company insiders that own Selecta Biosciences stock include Amir Nashat, David Abraham, Edwin M Kania, Jr, Lloyd P Johnston, Nanodimension Management Ltd, Peter Keller, Takashi Kei Kishimoto and Timothy A Springer. View Institutional Ownership Trends for Selecta Biosciences.

Who sold Selecta Biosciences stock? Who is selling Selecta Biosciences stock?

Selecta Biosciences' stock was sold by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., JPMorgan Chase & Co. and Morgan Stanley. Company insiders that have sold Selecta Biosciences stock in the last year include David Abraham, Edwin M Kania, Jr, Lloyd P Johnston, Peter Keller and Takashi Kei Kishimoto. View Insider Buying and Selling for Selecta Biosciences.

Who bought Selecta Biosciences stock? Who is buying Selecta Biosciences stock?

Selecta Biosciences' stock was acquired by a variety of institutional investors in the last quarter, including UBS Group AG, Candriam Luxembourg S.C.A., Hikari Power Ltd, Bank of New York Mellon Corp, Goldman Sachs Group Inc., Vanguard Group Inc. and Geode Capital Management LLC. Company insiders that have bought Selecta Biosciences stock in the last two years include Amir Nashat, Nanodimension Management Ltd and Timothy A Springer. View Insider Buying and Selling for Selecta Biosciences.

How do I buy Selecta Biosciences stock?

Shares of Selecta Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Selecta Biosciences' stock price today?

One share of Selecta Biosciences stock can currently be purchased for approximately $19.87.


MarketBeat Community Rating for Selecta Biosciences (NASDAQ SELB)
Community Ranking:  3.2 out of 5 (  )
Outperform Votes:  48 (Vote Outperform)
Underperform Votes:  26 (Vote Underperform)
Total Votes:  74
MarketBeat's community ratings are surveys of what our community members think about Selecta Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Selecta Biosciences (NASDAQ:SELB) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $28.33 (42.59% upside)

Analysts' Ratings History for Selecta Biosciences (NASDAQ:SELB)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/13/2017Canaccord GenuitySet Price TargetBuy$25.00LowView Rating Details
3/28/2017Needham & Company LLCReiterated RatingBuy$28.00HighView Rating Details
12/8/2016Stifel NicolausReiterated RatingBuy$23.00 -> $32.00N/AView Rating Details
(Data available from 6/27/2015 forward)

Earnings

Earnings History for Selecta Biosciences (NASDAQ:SELB)
Earnings by Quarter for Selecta Biosciences (NASDAQ:SELB)
Earnings History by Quarter for Selecta Biosciences (NASDAQ SELB)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/11/2017Q1 2017($1.22)($0.82)$0.14 millionViewN/AView Earnings Details
3/27/201712/31/2016($0.25)($0.77)$15.00 million$2.93 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Selecta Biosciences (NASDAQ:SELB)
Current Year EPS Consensus Estimate: $-3.34 EPS
Next Year EPS Consensus Estimate: $-2.66 EPS

Dividends

Dividend History for Selecta Biosciences (NASDAQ:SELB)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Selecta Biosciences (NASDAQ:SELB)
Institutional Ownership Percentage: 46.50%
Insider Trades by Quarter for Selecta Biosciences (NASDAQ:SELB)
Institutional Ownership by Quarter for Selecta Biosciences (NASDAQ:SELB)
Insider Trades by Quarter for Selecta Biosciences (NASDAQ:SELB)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/15/2017Lloyd P JohnstonCOOSell20,512$17.00$348,704.00View SEC Filing  
6/1/2017Timothy A SpringerDirectorBuy518$13.75$7,122.50View SEC Filing  
5/18/2017Timothy A SpringerDirectorBuy16,104$14.00$225,456.00View SEC Filing  
5/16/2017Edwin M. Kania, Jr.DirectorSell266,795$14.00$3,735,130.00View SEC Filing  
4/17/2017Lloyd P JohnstonCOOSell13,205$13.95$184,209.75View SEC Filing  
12/28/2016Takashi Kei KishimotoInsiderSell10,000$17.55$175,500.00View SEC Filing  
12/21/2016David AbrahamInsiderSell14,844$18.00$267,192.00View SEC Filing  
12/19/2016Peter KellerInsiderSell4,723$18.58$87,753.34View SEC Filing  
6/27/2016Amir NashatDirectorBuy150,000$14.00$2,100,000.00View SEC Filing  
6/27/2016Nanodimension Management LtdMajor ShareholderBuy385,000$14.00$5,390,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Selecta Biosciences (NASDAQ:SELB)
Latest Headlines for Selecta Biosciences (NASDAQ:SELB)
Source:
DateHeadline
americanbankingnews.com logo Analysts Set $26.67 Price Target for Selecta Biosciences, Inc. (SELB)
www.americanbankingnews.com - June 22 at 10:46 PM
americanbankingnews.com logoSelecta Biosciences, Inc. (SELB) COO Lloyd P. Johnston Sells 20,512 Shares
www.americanbankingnews.com - June 19 at 7:35 PM
finance.yahoo.com logoSelecta Biosciences Announces Addition of Patrick J. Zenner to Board of Directors
finance.yahoo.com - June 19 at 9:45 AM
finance.yahoo.com logoSelecta Biosciences (SELB) In Focus: Stock Moves 6.5% Higher
finance.yahoo.com - June 16 at 4:07 PM
finance.yahoo.com logoSelecta Biosciences Reports Data from Ongoing Phase 2 Trial of Lead Candidate, SEL-212, in Development for Chronic Severe Gout
finance.yahoo.com - June 15 at 4:38 PM
americanbankingnews.com logoSelecta Biosciences, Inc. (SELB) Expected to Post Earnings of -$0.86 Per Share
www.americanbankingnews.com - June 12 at 6:16 PM
finance.yahoo.com logoSelecta Biosciences Announces Upcoming Clinical Presentations
finance.yahoo.com - June 6 at 10:14 PM
finance.yahoo.com logoETFs with exposure to Selecta Biosciences, Inc. : June 6, 2017
finance.yahoo.com - June 6 at 10:14 PM
finance.yahoo.com logoSelecta Biosciences, Inc. :SELB-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017
finance.yahoo.com - June 3 at 12:07 AM
americanbankingnews.com logoZacks: Analysts Set $26.67 Price Target for Selecta Biosciences Inc (SELB)
www.americanbankingnews.com - June 2 at 7:34 AM
finance.yahoo.com logoSelecta Biosciences to Present at the Jefferies Global Healthcare Conference on June 7, 2017
finance.yahoo.com - May 31 at 12:33 PM
americanbankingnews.com logoSelecta Biosciences Inc (SELB) Director Buys $225,456.00 in Stock
www.americanbankingnews.com - May 19 at 7:58 PM
americanbankingnews.com logoInsider Selling: Selecta Biosciences Inc (SELB) Director Sells 266,795 Shares of Stock
www.americanbankingnews.com - May 16 at 7:14 PM
americanbankingnews.com logo-$0.86 EPS Expected for Selecta Biosciences Inc (SELB) This Quarter
www.americanbankingnews.com - May 16 at 9:20 AM
americanbankingnews.com logo Selecta Biosciences Inc (SELB) Receives Average Rating of "Strong Buy" from Analysts
www.americanbankingnews.com - May 16 at 8:06 AM
finance.yahoo.com logoEdited Transcript of SELB earnings conference call or presentation 11-May-17 9:00pm GMT
finance.yahoo.com - May 15 at 9:26 AM
finance.yahoo.com logoSelecta Biosciences Announces New Preclinical Gene Therapy Data at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
finance.yahoo.com - May 15 at 9:26 AM
americanbankingnews.com logoSelecta Biosciences Inc (SELB) PT Set at $25.00 by Canaccord Genuity
www.americanbankingnews.com - May 15 at 12:34 AM
americanbankingnews.com logoSelecta Biosciences Inc (SELB) Posts Quarterly Earnings Results, Beats Expectations By $0.40 EPS
www.americanbankingnews.com - May 12 at 12:14 PM
streetinsider.com logoSelecta Biosciences (SELB) Commences Dosing in Phase 1 Trial of Nicotine Vaccine for Smoking Cessation
www.streetinsider.com - May 12 at 1:14 AM
finance.yahoo.com logoSelecta Biosciences Commences Dosing in Phase 1 Clinical Trial of Nicotine Vaccine for Smoking Cessation and Relapse Prevention
finance.yahoo.com - May 11 at 8:14 PM
finance.yahoo.com logoSelecta Biosciences Announces First Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - May 11 at 8:14 PM
finance.yahoo.com logoSelecta Biosciences to Report First Quarter 2017 Financial Results on Thursday, May 11, 2017
finance.yahoo.com - May 4 at 11:14 AM
americanbankingnews.com logoZacks: Selecta Biosciences Inc (SELB) Given $26.67 Consensus Target Price by Analysts
www.americanbankingnews.com - May 4 at 12:12 AM
fool.com logoReady for Launch: Selecta Biosciences Inc. Jumps as Much as 16%
www.fool.com - May 2 at 5:22 PM
finance.yahoo.com logoSelecta Biosciences Obtains License for Recombinant Immunotoxin LMB-100 from National Cancer Institute (NCI) for Pancreatic Cancer, Mesothelioma and Other Cancers
finance.yahoo.com - May 2 at 9:33 AM
finance.yahoo.com logoSelecta Biosciences Announces Presentations at the 20th Annual Meeting of the American Society of Gene & Cell Therapy
finance.yahoo.com - May 1 at 8:46 AM
finance.yahoo.com logoETFs with exposure to Selecta Biosciences, Inc. : April 26, 2017
finance.yahoo.com - April 26 at 4:15 PM
finance.yahoo.com logoSelecta Biosciences to Present at Two Upcoming Investor Conferences in May
finance.yahoo.com - April 26 at 9:24 AM
americanbankingnews.com logoSelecta Biosciences Inc (SELB) Short Interest Update
www.americanbankingnews.com - April 26 at 12:40 AM
americanbankingnews.com logoSelecta Biosciences Inc (SELB) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - April 20 at 8:23 PM
americanbankingnews.com logoInsider Selling: Selecta Biosciences Inc (SELB) COO Sells 13,205 Shares of Stock
www.americanbankingnews.com - April 18 at 7:55 PM
americanbankingnews.com logoSelecta Biosciences Inc (SELB) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - April 8 at 7:25 AM
finance.yahoo.com logoETFs with exposure to Selecta Biosciences, Inc. : April 5, 2017
finance.yahoo.com - April 7 at 12:30 PM
finance.yahoo.com logoSELECTA BIOSCIENCES INC Financials
finance.yahoo.com - March 31 at 7:58 PM
finance.yahoo.com logoEdited Transcript of SELB earnings conference call or presentation 27-Mar-17 9:00pm GMT
finance.yahoo.com - March 28 at 7:35 PM
americanbankingnews.com logoSelecta Biosciences Inc (SELB) Earns Buy Rating from Needham & Company LLC
www.americanbankingnews.com - March 28 at 9:50 AM
streetinsider.com logoAfter-Hours Stock Movers 03/27: (PSIX) (OCN) (RHT) Higher; (CYRX) (EVH) (STOR) Lower (more...)
www.streetinsider.com - March 28 at 9:27 AM
rttnews.com logoFDA Nod For TSRO, Déjà Vu For ARQL, FOMX Plunges On Trial Data, SELB Abuzz
www.rttnews.com - March 28 at 9:27 AM
biz.yahoo.com logoSELECTA BIOSCIENCES INC Files SEC form 10-K, Annual Report
biz.yahoo.com - March 28 at 9:27 AM
finance.yahoo.com logoSelecta Biosciences to Present at the Needham Healthcare Conference on April 4, 2017
finance.yahoo.com - March 28 at 9:27 AM
americanbankingnews.com logoSelecta Biosciences Inc (SELB) Posts Earnings Results, Misses Estimates By $0.52 EPS
www.americanbankingnews.com - March 28 at 9:05 AM
finance.yahoo.com logoSelecta Biosciences Announces Fourth Quarter and Year End 2016 Financial Results and Provides Corporate Update
finance.yahoo.com - March 27 at 6:57 PM
biz.yahoo.com logoSELECTA BIOSCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure,
biz.yahoo.com - March 27 at 6:57 PM
biz.yahoo.com logoSelecta Biosciences Inc Earnings Call scheduled for 5:00 pm ET today
biz.yahoo.com - March 27 at 6:57 PM
biz.yahoo.com logoQ4 2016 Selecta Biosciences Inc Earnings Release - After Market Close
biz.yahoo.com - March 27 at 9:14 AM
americanbankingnews.com logoSelecta Biosciences Inc (SELB) Set to Announce Earnings on Monday
www.americanbankingnews.com - March 25 at 8:39 PM
nasdaq.com logoSelecta Biosciences to Report Fourth Quarter and Year End 2016 Financial Results on Monday, March
www.nasdaq.com - March 21 at 7:29 PM
americanbankingnews.com logoBrokerages Expect Selecta Biosciences Inc (SELB) to Announce $0.32 Earnings Per Share
www.americanbankingnews.com - March 20 at 12:22 PM
finance.yahoo.com logoSelecta Biosciences to Report Fourth Quarter and Year End 2016 Financial Results on Monday, March 27, 2017
finance.yahoo.com - March 20 at 9:05 AM

Social

Chart

Selecta Biosciences (SELB) Chart for Tuesday, June, 27, 2017

This page was last updated on 6/27/2017 by MarketBeat.com Staff